DNA-based strategies for blocking HMGB1 cytokine activity: design, synthesis and preliminary \textit{in vitro/in vivo} assays of DNA and DNA-like duplexes

Domenica Musumeci\textsuperscript{1*}, Enrico M. Bucci\textsuperscript{1}, Giovanni N. Roviello\textsuperscript{1}, Roberto Sapio\textsuperscript{2}, Margherita Valente\textsuperscript{2}, Maria Moccia\textsuperscript{1}, Marco E. Bianchi\textsuperscript{3} and Carlo Pedone\textsuperscript{1}

\textsuperscript{1} Istituto di Biostrutture e Bioimmagini – CNR, via Mezzocannone 16, 80134 Napoli, Italy;
\textsuperscript{2} Bionucleon Srl, via Ribes 5, 10010 Colleretto Giacosa (TO), Italy;
\textsuperscript{3} DIBIT, San Raffaele University, via Olgettina 58, 20132 Milano, Italy.

* Correspondence should be addressed to Domenica Musumeci (domymusu@alice.it); via Mezzocannone 16, 80134 Napoli, Italy; Tel: +39-(0)81-2534585; Fax: +39-(0)81-2534574.
Figure S1

CD titration of *chim 2A* duplex with HMGB1.
Figure S2

Chemotaxis assays: in treatments from 3 to 6, from 7 to 10 and from 11 to 14, increasing amounts (3, 10, 30 and 100 nM) of chim2A duplex, DNA 2A duplex, and chimeric single strand f were used.